

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PATENT**  
Attorney Docket No.: 15270J-004760US  
Client Ref. No.: 209-US-CIP8B

#10  
AB  
01/16/02

On October 18, 2001

TOWNSEND and TOWNSEND and CREW LLP

*Patricia J. Alli*



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Schenk et al.

Application No.: 09/580,018

Filed: May 26, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon

Art Unit: 1647

**RESPONSE**

RECEIVED  
TECH CENTER 1600  
JAN 15 2002  
2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper is submitted in response to the Office Action mailed September 24, 2001.

**REMARKS**

The Office Action mailed September 24, 2001 is a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicants mailed a Communication Under 37 C.F.R. §§ 1.821-1.825 and Preliminary Amendment to the USPTO on September 11, 2001, as evidenced by the attached return receipt postcard bearing the PTO OIPE date stamp of September 19, 2001. A PAIR report, attached, shows a pre-examination amendment was entered